文献速递关节外科

地塞米松对初次全关节置换术后患者血糖控制的影响:一项随机双盲对照试验

Effects of Dexamethasone on Postoperative Glycemic Control in Patients After Primary Total Joint Arthroplasty: A Randomized Double-Blind Controlled Trial.
PubMed 文献 · J Arthroplasty · 2024-04-12

该随机双盲对照试验纳入135例无糖尿病患者,比较术前静脉注射生理盐水、10 mg地塞米松与20 mg地塞米松对全关节置换术后血糖的影响。结果显示地塞米松组术后第0天和第1天空腹血糖高于安慰剂组,20 mg组术后第1天餐后血糖高于其他两组,但术前静脉注射地塞米松与空腹血糖≥140 mg/dL或餐后血糖≥180 mg/dL无关,三组并发症无差异。

要点

  • 无糖尿病患者全关节置换术前静脉注射10或20 mg地塞米松对术后血糖仅有短暂影响。
  • 术前糖化血红蛋白升高分别增加空腹血糖≥140 mg/dL和餐后血糖≥180 mg/dL的风险。
  • 术前静脉注射地塞米松与空腹血糖≥140 mg/dL或餐后血糖≥180 mg/dL无关。

核心结论

  • 无糖尿病患者全关节置换术前静脉注射10或20 mg地塞米松对术后血糖有短暂影响,三组术后并发症无差异。
  • 术前糖化血红蛋白升高增加空腹血糖≥140 mg/dL和餐后血糖≥180 mg/dL的风险,而术前静脉注射地塞米松与上述血糖阈值无关。

研究设计与样本

  • 随机双盲对照试验,共纳入135例无糖尿病患者,随机分为三组:术前静脉注射生理盐水(A组,安慰剂组)、术前静脉注射10 mg地塞米松(B组)和术前静脉注射20 mg地塞米松(C组)。
  • 主要结局为术后空腹血糖,次要结局为术后餐后血糖,并记录并发症发生率,同时分析空腹血糖≥140 mg/dL和餐后血糖≥180 mg/dL的风险因素。

主要发现

  • 术后第0天和第1天,B组和C组空腹血糖高于A组。
  • 术后第1天,A组和B组餐后血糖低于C组。
  • 术后第1天之后未检测到空腹血糖或餐后血糖的差异。
  • 术前糖化血红蛋白升高分别增加空腹血糖≥140 mg/dL和餐后血糖≥180 mg/dL的风险。
  • 术前静脉注射地塞米松与空腹血糖≥140 mg/dL或餐后血糖≥180 mg/dL无关,三组术后并发症无差异。

关键数值与推荐

  • 术前糖化血红蛋白阈值(无论是否使用地塞米松或其剂量)增加空腹血糖≥140 mg/dL和餐后血糖≥180 mg/dL风险的阈值分别为5.75%和5.85%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients undergoing total joint arthroplasty, the use of dexamethasone (DEX) may cause perioperative blood glucose (BG) disorders, leading to complications even in patients who do not have diabetes. We aimed to evaluate the effects of different DEX doses on perioperative BG levels. METHODS: A total of 135 patients who do not have diabetes were randomized into three groups: preoperative intravenous (IV) injection of normal saline (Group A, the placebo group), preoperative IV injection of 10 mg DEX (Group B), and preoperative IV injection of 20 mg DEX (Group C). Postoperative fasting BG (FBG) levels were designated as the primary outcome, while postoperative postprandial BG (PBG) levels were assigned as the secondary outcome. The incidence of complications was recorded. We also investigated the risk factors for FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL. RESULTS: The FBG levels were higher in Groups B and C than in Group A on postoperative days (PODs) 0 and 1. The PBG levels were lower for Groups A and B compared to Group C on POD 1. No differences in FBG or PBG were detected beyond POD 1. Elevated preoperative glycosylated hemoglobin A1c levels increased the risk of FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL, respectively. However, preoperative IV injection of DEX was not associated with FBG ≥ 140 mg/dL or PBG ≥ 180 mg/dL. No differences were found in postoperative complications among the three groups. CONCLUSIONS: The preoperative IV administration of 10 or 20 mg DEX in patients who do not have diabetes showed transient effects on postoperative BG after total joint arthroplasty. The preoperative glycosylated hemoglobin A1c level threshold (regardless of the administration or dosage of DEX) that increased the risk for the occurrence of FBG ≥ 140 mg/dL and PBG ≥ 180 mg/dL was 5.75 and 5.85%, respectively.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Liu XY, Mou P, Cao J, et al. Effects of Dexamethasone on Postoperative Glycemic Control in Patients After Primary Total Joint Arthroplasty: A Randomized Double-Blind Controlled Trial. J Arthroplasty. 2024. PMID: 38614358. doi:10.1016/j.arth.2024.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。